Ohcanbohtosat - Daniel Robbins

  • Čájehuvvo 1 - 9 / 9
Aiddostahte ozu
  1. 1
    Movement Demands in Australian Rules Football as Indicators of Muscle Damage

    Movement Demands in Australian Rules Football as Indicators of Muscle Damage Dahkki Warren Young, Jamie Hepner, Daniel Robbins

    Almmustuhtton 2012
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Agonist-Antagonist Paired Set Resistance Training: A Brief Review

    Agonist-Antagonist Paired Set Resistance Training: A Brief Review Dahkki Daniel Robbins, Warren Young, David G. Behm, Warren Payne

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    The Effect of a Complex Agonist and Antagonist Resistance Training Protocol on Volume Load, Power Output, Electromyographic Responses, and Efficiency

    The Effect of a Complex Agonist and Antagonist Resistance Training Protocol on Volume Load, Power Output, Electromyographic Responses, and Efficiency Dahkki Daniel Robbins, Warren Young, David G. Behm, Warren Payne

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Catalytic enantioselective addition of organoboron reagents to fluoroketones controlled by electrostatic interactions

    Catalytic enantioselective addition of organoboron reagents to fluoroketones controlled by electrostatic interactions Dahkki KyungA Lee, Daniel L. Silverio, Sebastian Torker, Daniel Robbins, Fredrik Hæffner, Farid W. van der Mei, Amir H. Hoveyda

    Almmustuhtton 2016
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies

    Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies Dahkki Daniel Robbins, Mark Noviski, Ryan B. Rountree, May Tan, Nivetha Brathaban, Timothy Ingallinera, Dane E. Karr, Aileen Kelly, Zef Konst, Jun Ma, Austin Tenn-McClellan, Jenny McKinnell, Luz Perez, Cristiana Guiducci, Gwenn M. Hansen, Arthur Sands

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

    Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies Dahkki Daniel Robbins, Aileen Kelly, May Tan, Joel McIntosh, Jeffrey Wu, Zef Konst, Daisuke Kato, Ge Peng, Jeff Mihalic, Dahlia R. Weiss, Luz Perez, Jennifer Tung, Anna Kolobova, Sasha Borodovsky, Ryan B. Rountree, Austin Tenn-McClellan, Mark Noviski, Jordan Ye, Stephen E. Basham, Timothy Ingallinera, Jenny McKinnell, Dane E. Karr, Janine Powers, Cristiana Guiducci, Arthur Sands

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

    Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B C... Dahkki Daniel Robbins, Mark Noviski, Ying Siow Tan, Zef A. Könst, Aileen Kelly, P Auger, Nivetha Brathaban, Robert Cass, Ming Liang Chan, Ganesh Cherala, Matthew C. Clifton, Stefan Gajewski, Timothy G. Ingallinera, Dane E. Karr, Daisuke Kato, Jun Ma, Jenny McKinnell, Joel McIntosh, Jeff Mihalic, Brent Murphy, Panga Jaipal Reddy, Ge Peng, Janine Powers, Luz Perez, Ryan B. Rountree, Austin Tenn-McClellan, Arthur Sands, Dahlia R. Weiss, Jeffrey Wu, Jordan Ye, Cristiana Guiducci, Gwenn M. Hansen, Frederick Cohen

    Almmustuhtton 2024
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors

    Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors Dahkki Jeffrey W. Johannes, Stephanie M. Bates, Carl Beigie, Matthew A. Belmonte, John Breen, Shenggen Cao, Paolo A. Centrella, Matthew Clark, John W. Cuozzo, Christoph E. Dumelin, Andrew D. Ferguson, Sevan Habeshian, David Hargreaves, Camil Joubran, Steven L. Kazmirski, Anthony D. Keefe, Michelle L. Lamb, Haiye Lan, Yunxia Li, Hao Ma, Scott N. Mlynarski, Martin J. Packer, Philip B. Rawlins, Daniel Robbins, Haidong Shen, Eric A. Sigel, Holly H. Soutter, Nancy Su, Dawn M. Troast, Haiyun Wang, Kate F. Wickson, Chengyan Wu, Ying Zhang, Qiuying Zhao, Xiaolan Zheng, Alexander W. Hird

    Almmustuhtton 2016
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

    Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia Dahkki Adriana E. Tron, Matthew A. Belmonte, Ammar Adam, Brian Aquila, Lawrence Boise, Elisabetta Chiarparin, Justin Cidado, Kevin J. Embrey, Eric T. Gangl, Francis D. Gibbons, Gareth P. Gregory, David Hargreaves, J. Adam Hendricks, Jeffrey W. Johannes, Ricky W. Johnstone, Steven L. Kazmirski, Jason G. Kettle, Michelle L. Lamb, Shannon M. Matulis, Ajay K. Nooka, Martin J. Packer, Bo Peng, Philip B. Rawlins, Daniel Robbins, Alwin G. Schuller, Nancy Su, Wenzhan Yang, Qing Ye, Xiaolan Zheng, J. Paul Secrist, Edwin Clark, David M. Wilson, Stephen E. Fawell, Alexander W. Hird

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: